EUVIMEDEUVIMED entdecken
Open Access

Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity

Andrew W Daman, Anthony C Antonelli, Gil Redelman-Sidi, Lucinda Paddock, Shireen Khayat, Mythili Ketavarapu, Jin Gyu Cheong, Leonardo F Jurado, Anna Benjamin, Song Jiang, Dughan Ahimovic, Victoria R Lawless und 9 weitere

Cancer Cell · 2025-08 · 43 (8) · 1442-1459.e10

DOI: 10.1016/j.ccell.2025.05.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2025-08. Verfasst von Andrew W Daman und 20 weiteren Autor:innen. Beteiligte Einrichtung: Immunology and Microbial Pathogenesis Program, Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA; Department of Patholog…. Hauptthemen laut MEDLINE: Immunotherapy, Hematopoiesis, BCG Vaccine, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium bovis Bacillus Calmette-Guérin (BCG) is the vaccine against tuberculosis and an immunotherapy for bladder cancer. When administered intravenously, BCG reprograms bone marrow hematopoietic stem and progenitor cells (HSPCs), leading to heterologous protection against infections. Whether HSPC reprogramming contributes to the anti-tumor effects of BCG administered into the bladder is unknown. We demonstrate that BCG administered in the bladder colonizes the bone marrow and, in both mice and humans, reprograms HSPCs to alter and amplify myelopoiesis. BCG-reprogrammed HSPCs are sufficient to confer augmented anti-tumor immunity through production of neutrophils, monocytes, and dendritic cells that broadly remodel the tumor microenvironment, drive T cell-dependent anti-tumor responses, and synergize with checkpoint blockade. We conclude that bladder BCG acts systemically through hematopoiesis, highlighting the broad potential of HSPC reprogramming to enhance the innate drivers of T cell-dependent tumor immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyHematopoiesisBCG VaccineUrinary Bladder NeoplasmsMyeloid CellsAnimalsMiceHumansTumor MicroenvironmentHematopoietic Stem CellsMice, Inbred C57BLMycobacterium bovisFemaleCellular ReprogrammingNeutrophils

Stichwörter der Autor:innen

BCGbladder cancerepigeneticshematopoiesisimmunotherapyinnate immune memorytrained immunitytumor immunity

Substanzen

BCG Vaccine

Autor:innen und Institutionen

  • Immunology and Microbial Pathogenesis Program, Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA; Department of Pathology and Laboratory Medicine, Division of Cell and Cancer Pathobiology, W…
  • Immunology and Microbial Pathogenesis Program, Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA; Immunology Program, Sloan Kettering Institute, New York, NY, USA.
  • Infectious Diseases Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Pathology and Laboratory Medicine, Division of Cell and Cancer Pathobiology, Weill Cornell Medicine, New York, NY, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA; Computational and Systems Biol…
  • Pharmacology Program, Weill Cornell Medicine Graduate School of Medical Sciences, New York, NY, USA.
  • Department of Pathology and Laboratory Medicine, Division of Cell and Cancer Pathobiology, Weill Cornell Medicine, New York, NY, USA.

Förderung

  • NHLBI NIH HHS
  • NIGMS NIH HHS
  • NCI NIH HHS
  • NIAID NIH HHS
  • National Institutes of Health
  • Royal Society of Canada
  • Quebec Health Research Fund
  • National Science Foundation

Zitieren

APA

Daman, A. W., Antonelli, A. C., Redelman-Sidi, G., Paddock, L., Khayat, S., Ketavarapu, M., Cheong, J. G., Jurado, L. F., Benjamin, A., Jiang, S., Ahimovic, D., Lawless, V. R., Bale, M. J., Loutochin, O., McPherson, V. A., Divangahi, M., Niec, R. E., Pe'er, D., Pietzak, E., …, & Glickman, M. S. (2025). Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity. Cancer Cell, 43(8), 1442-1459.e10. https://doi.org/10.1016/j.ccell.2025.05.002

Vancouver

Daman AW, Antonelli AC, Redelman-Sidi G, Paddock L, Khayat S, Ketavarapu M, et al. Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity. Cancer Cell. 2025;43(8):1442-1459.e10. doi:10.1016/j.ccell.2025.05.002

BibTeX
@article{Daman2025,
  author = {Daman, Andrew W and Antonelli, Anthony C and Redelman-Sidi, Gil and Paddock, Lucinda and Khayat, Shireen and Ketavarapu, Mythili and Cheong, Jin Gyu and Jurado, Leonardo F and Benjamin, Anna and Jiang, Song and Ahimovic, Dughan and Lawless, Victoria R and Bale, Michael J and Loutochin, Oleg and McPherson, Victor A and Divangahi, Maziar and Niec, Rachel E and Pe'er, Dana and Pietzak, Eugene and Josefowicz, Steven Z and Glickman, Michael S},
  title = {Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity},
  journal = {Cancer Cell},
  year = {2025},
  volume = {43},
  number = {8},
  pages = {1442--1459.e10},
  doi = {10.1016/j.ccell.2025.05.002}
}
Kostenlos starten →